The EU Commission announces interim measures following a breach of the standstill obligation between two healthcare companies specialized in genomic sequencing (Grail / Illumina)

Mergers: The Commission adopts a Statement of Objections in view of adopting interim measures following Illumina's early acquisition of GRAIL* The European Commission has sent a Statement of Objections to Illumina and GRAIL informing them of the interim measures it intends to adopt following the companies' alleged breach of the standstill obligation under the EU Merger Regulation. These measures aim to restore and maintain effective competition while the Commission's review of the acquisition of GRAIL by Illumina is pending. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “Illumina and GRAIL completed their merger, while our investigation is still ongoing. Under our rules, companies have to wait for the Commission's clearance before implementing

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission announces interim measures following a breach of the standstill obligation between two healthcare companies specialized in genomic sequencing (Grail / Illumina), 20 September 2021, e-Competitions September 2021, Art. N° 102346

Visites 586

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues